References: ZOMETA® Dosing For Tumour-Induced Hypercalcaemia (TIH)

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

Zometa Dosing & Administration: Dosing for TIH

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

References: 1. ZOMETA^® Summary of Product Characteristics. Novartis Pharma AG. 2. Major P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.Oncologist. 2002;7:481-491. 3. ZOMETA US Prescribing Information. Novartis Pharmaceuticals Corporation.

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.